½ÃÀ庸°í¼­
»óǰÄÚµå
1786541

¼¼°èÀÇ PET ¹æ»ç¼º ÃßÀûÀÚ ½ÃÀå : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2025-2032³â)

PET Radioactive Tracers Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Persistence Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 350 Pages | ¹è¼Û¾È³» : 2-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Persistence Market Research´Â PET ¹æ»ç¼º ÃßÀûÀÚ ¼¼°è ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ º¸°í¼­¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ º¸°í¼­´Â ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, µ¿Çâ, ±âȸ ¹× °úÁ¦¸¦ Æ÷ÇÔÇÑ Áß¿äÇÑ ½ÃÀå ¿ªÇÐÀ» öÀúÈ÷ Æò°¡ÇÏ°í ½ÃÀå ±¸Á¶¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÅëÂû·ÂÀ» Á¦°øÇÕ´Ï´Ù.

ÁÖ¿ä ÀλçÀÌÆ®

  • PET ¹æ»ç¼º ÃßÀûÀÚ ½ÃÀå ±Ô¸ð(2025³â) : 10¾ï 6,980¸¸ ´Þ·¯
  • ½ÃÀå ¿¹ÃøÄ¡(2032³â) :17¾ï670¸¸
  • ¼¼°è ½ÃÀå ¼ºÀå·ü(CAGR 2025³â-2032³â) : 6.9%

PET ¹æ»ç¼º ÃßÀûÀÚ ½ÃÀå : Á¶»ç ¹üÀ§

¾çÀüÀÚ ¹æ»ç¼± ´ÜÃþÃÔ¿µ(PET) ¹æ»ç¼º ÃßÀûÀÚ´Â ÇÙÀÇÇÐ À̹Ì¡¿¡¼­ Áß¿äÇÑ ±¸¼º¿ä¼ÒÀÌ¸ç ºÐÀÚ ¼öÁØ¿¡¼­ »ý¸®ÇÐÀû °úÁ¤ÀÇ ½Ç½Ã°£ ½Ã°¢È­¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÃßÀûÀÚ´Â ÁÖ·Î ºÒ¼Ò-18, ź¼Ò-11, °¥·ý-68 µîÀÇ µ¿À§¿ø¼Ò·Î Ç¥ÁöµÇ¾î ÀÖÀ¸¸ç, Á¾¾çÇÐ, ½ÉÀ庴ÇÐ, ½Å°æÇÐ µîÀÇ ¿ëµµ¿¡ ³Î¸® »ç¿ëµË´Ï´Ù. PET ¹æ»ç¼º ÃßÀûÀÚ ½ÃÀåÀº º´¿ø, ¿µ»ó Áø´Ü¼¾ÅÍ, ¿¬±¸ ±â°ü¿¡ ¼­ºñ½º¸¦ Á¦°øÇϰí Á¤È®ÇÑ Áø´Ü, Áúº´ÀÇ º´±â ºÐ·ù, Ä¡·á ¸ð´ÏÅ͸µ, ¾à¹° °³¹ßÀ» Áö¿øÇÕ´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº ¾Ï°ú ½Å°æ ÁúȯÀÇ À¯º´·ü Áõ°¡, °í±Þ ¿µ»ó Áø´Ü ¾ç½Ä¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÀÓ»ó ¹× ÀüÀÓ»ó¿¡¼­ÀÇ PET ¿µ»ó Áø´ÜÀÇ ÀÌ¿ë È®´ëÀÔ´Ï´Ù.

½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ :

¼¼°èÀÇ PET ¹æ»ç¼º ÃßÀûÀÚ ½ÃÀåÀº ¾ÏÀ̳ª ¾ËÃ÷ÇÏÀ̸Ӻ´ µî Á¤¹ÐÇϰí Á¶±â Áø´Ü À̹Ì¡À» ÇÊ¿ä·Î ÇÏ´Â ¸¸¼º ÁúȯÀÇ ºÎ´ã Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÃßÁøµÇ°í ÀÖ½À´Ï´Ù. PET/CT³ª PET/MRI ½Ã½ºÅÛ°ú °°Àº ÇÏÀ̺긮µå À̹Ì¡ ±â¼úÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ÃßÀûÀÚ ¼ö¿ä¸¦ ´õ¿í ÀÚ±ØÇϰí ÀÖ½À´Ï´Ù. ƯÁ¤ ¼ö¿ëü ¹× ´ë»ç °æ·Î¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â ¹æ»ç¼º ÀǾàǰÀ» Æ÷ÇÔÇÑ ÃßÀûÀÚ °³¹ßÀÇ Áö¼ÓÀûÀÎ Çõ½ÅÀº Áø´Ü Á¤È®µµ¸¦ ³ôÀ̰í ÀÓ»óÀû À¯¿ë¼ºÀ» È®´ëÇÕ´Ï´Ù. ¶ÇÇÑ, ºÐÀÚ À̹Ì¡ ¿¬±¸¿¡ ´ëÇÑ Á¤ºÎÀÇ ÀÚ±Ý Áö¿ø, ¼±Áø±¹ ½ÃÀåÀÇ À¯¸®ÇÑ »óȯ ½Ã³ª¸®¿À, PETÀÇ ÀÓ»óÀû ÀÌÁ¡¿¡ ´ëÇÑ ÀÓ»óÀÇÀÇ ÀÇ½Ä Áõ°¡°¡ ½ÃÀåÀÇ °ßÁ¶ÇÑ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ :

À¯¸ÁÇÑ Àü¸Á¿¡µµ ºÒ±¸Çϰí, PET ¹æ»ç¼º ÃßÀû±â ½ÃÀåÀº ¸î¸î Á¦¾à¿¡ Á÷¸éÇϰí ÀÖ½À´Ï´Ù. ¿©±â¿¡´Â PET À̹Ì¡ ÀýÂ÷ÀÇ ºñ¿ëÀÌ ³ô°í ÃßÀûÀÚÀÇ ¹Ý°¨±â°¡ ª¾ÆÁö´Â µîÀÌ Æ÷ÇÔµÇ¸ç »çÀÌŬ·ÎÆ®·Ð ½Ã¼³¿¡ ´ëÇÑ ±ÙÁ¢¼º°ú ½Å·Ú¼ºÀÌ ³ôÀº ¹æ»ç¼º ÀǾàǰ °ø±Þ¸ÁÀÌ ÇÊ¿äÇÕ´Ï´Ù. »õ·Î¿î ÃßÀûÀÚÀÇ ½ÂÀΰú Á¦Á¶¿¡¼­ ±ÔÁ¦»óÀÇ Àå¾Ö¹°, ¹æ»ç¼º ¹°ÁúÀÇ Ãë±Þ ¹× ¿î¼ÛÀ» À§ÇÑ º¹ÀâÇÑ ¹°·ù°¡ ¿î¿µ»óÀÇ °úÁ¦¸¦ ³º°í ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ÀúÀÚ¿ø ȯ°æ¿¡¼­´Â PET À̹Ì¡¿¡ ´ëÇÑ Á¢±ÙÀÌ Á¦ÇѵǾî ÀÖ¾î ¼÷·ÃµÈ ÇÙÀÇÇÐ Àü¹®°¡°¡ ºÎÁ·Çϱ⠶§¹®¿¡ ƯÈ÷ ½ÅÈï±¹¿¡¼­´Â º¸±ÞÀÇ ¹æÇذ¡ µÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ±âȸ :

PET ¹æ»ç¼º ÃßÀûÀÚ ½ÃÀåÀº ¹æ»ç¼º ÃßÀûÀÚ ½ÃÀå °³Ã´°ú ¹æ»ç¼º ÀǾàǰ Á¦Á¶ÀÇ ÀÚµ¿È­¿¡ À־ÀÇ ±â¼ú Áøº¸¿¡ ÃßÁøµÇ¾î Å« ¼ºÀå ±âȸ¸¦ °¡Á®¿À°í ÀÖ½À´Ï´Ù. ¸é¿ªÁ¾¾çÇÐ, ½ÉÇ÷°ü À̹Ì¡, ½Å°æÅðÇ༺ Áúȯ ¸ð´ÏÅ͸µÀ» À§ÇÑ »õ·Î¿î ÃßÀûÀÚÀÇ ÃâÇöÀº ÀÓ»ó ÀÀ¿ëÀ» È®´ëÇϰí Á¤¹ÐÀÇ·á Á¢±ÙÀ» Áö¿øÇÕ´Ï´Ù. °³¹ßµµ»ó±¹¿¡¼­ PET À̹Ì¡ ½Ã¼³ÀÇ ¼³¸³ÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç ¹æ»ç¼º ÀǾàǰ ÀÎÇÁ¶ó¸¦ °³¼±Çϱâ À§ÇÑ °ü¹Î ÆÄÆ®³Ê½Ê°ú ÇÔ²² ¹Ì°³Ã´ÀÇ °¡´É¼ºÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, Ç¥Àû Ä¡·á¸¦ À§ÇÑ µ¿¹ÝÁø´ÜÁ¦ °³¹ßÀ» À§ÇÑ Á¦¾à ±â¾÷°ú À̹ÌÁö ¼Ö·ç¼Ç Á¦°ø¾÷ü¿ÍÀÇ Çù¾÷Àº ½ÃÀåÀÇ ¹Ì·¡¸¦ °­È­Çϰí ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

  • PET ¹æ»ç¼º ÃßÀûÀÚ ½ÃÀåÀÇ ¼¼°è ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?
  • À̹Ì¡ ¼¾ÅÍ Àüü¿¡¼­ ÃßÀûÀÚÀÇ ÀÌ¿ëÀ» ÃËÁøÇϰí ÀÖ´Â µ¿À§¿ø¼Ò³ª ÀÓ»ó ¿ëµµ´Â ¹«¾ùÀΰ¡?
  • ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©°ú ±â¼ú Çõ½ÅÀº °æÀï ±¸µµ¸¦ ¾î¶»°Ô Çü¼ºÇϴ°¡?
  • PET ¹æ»ç¼º ÃßÀûÀÚ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº ´©±¸À̸ç, ¾î¶² Àü·«À» äÅÃÇϰí Àִ°¡?
  • ÃßÀûÀÚ °³¹ß°ú äÅÿ¡ °üÇÑ »õ·Î¿î µ¿Çâ°ú ÇâÈÄÀÇ ¹æÇ⼺Àº?

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå °³¿ä

  • ½ÃÀå ¹üÀ§/ºÐ·ù
  • ½ÃÀåÀÇ Á¤ÀÇ/¹üÀ§/Á¦ÇÑ
  • Æ÷ÇÔ°ú Á¦¿Ü

Á¦3Àå ÁÖ¿ä ½ÃÀå µ¿Çâ

  • ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä µ¿Çâ
  • Çõ½Å/°³¹ß µ¿Çâ

Á¦4Àå Áß¿ä ¼º°ø ¿äÀÎ

  • PET ½ºÄ³³Ê µµÀÔ ½Ã³ª¸®¿À
  • ±¹°¡º° PET ½ºÄµ °Ç¼ö
  • Áúº´ ¿ªÇÐ
  • Á¦Ç°ÀÇ Ã¤ÅÃ/»ç¿ë »óȲ ºÐ¼®
  • ±ÔÁ¦ ½ÂÀÎ °æ·Î
  • »óȯ ½Ã³ª¸®¿À
  • ±â¼úÀÇ Áøº¸
  • ÀûÁ¤ Á¦Á¶ ±Ô¹ü(cGMP)
  • ¹ë·ùüÀÎ ºÐ¼®
  • ǰÁú ±âÁØ/ÀÎÁ¤
  • PESTEL ºÐ¼®
  • Porter's Five Forces ºÐ¼®

Á¦5Àå ½ÃÀå ¹è°æ

  • °Å½Ã°æÁ¦ ¿äÀÎ
  • ¿¹Ãø ¿äÀÎ- °ü·Ã¼º°ú ¿µÇâ
  • ½ÃÀå ¿ªÇÐ

Á¦6Àå COVID-19 À§±â ºÐ¼®

  • 2021³â ½ÃÀå ½Ã³ª¸®¿À
  • COVID-19¿Í ¿µÇ⠺м®
    • Á¦Ç°º°
    • ¿ëµµº°
    • ÃÖÁ¾ »ç¿ëÀÚº°
    • Áö¿ªº°

Á¦7Àå ¼¼°è ½ÃÀå ¼ö¿ä ºÐ¼®

  • ½ÃÀå ¸ÅÃâÀÇ ½ÇÀû ºÐ¼®, 2019³â-2024³â
  • ÇöÀç ¹× Àå·¡ ½ÃÀå ¸ÅÃâ ¿¹Ãø, 2025³â-2032³â
    • Àü³â´ëºñ ¼ºÀå µ¿Ç⠺м®
    • Àý´ëÀû ¼öÀÍ ±âȸ ºÐ¼®

Á¦8Àå Á¦Ç°º° ¼¼°è ½ÃÀå ºÐ¼®

  • ¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
  • Á¦Ç°º° ½ÃÀå ±Ô¸ð ÃßÀÌ ºÐ¼®, 2019³â-2024³â
  • Á¦Ç°º° ÇöÀç ¹× Àå·¡ ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø, 2025³â-2032³â
    • F-18
      • ÇÁ·Ñº£Å¸ÇÊ
      • ÇÁ·Ñº£Å¸º¥
      • Ç®Å׸ÞŸ¸ô
      • Ç÷絥¿Á½Ã±Û·çÄÚ½º
      • ºÒÈ­³ªÆ®·ý
      • ±âŸ
    • C-11
      • Äݸ°
      • ¸ÞƼ¿À´Ñ
      • ±âŸ
    • Ga-68
      • DOTA-TOC
      • µµÅ¸Å×
      • µµÅ¸³ì
      • ±âŸ
    • O-15
    • N-13
    • Cu-64
  • ÃÖÁ¾ »ç¿ëÀÚº° ½ÃÀå ¸Å·Â ºÐ¼®

Á¦9Àå ¿ëµµº° ¼¼°è ½ÃÀå ºÐ¼®

  • ¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
  • ¿ëµµº° ½ÃÀå ±Ô¸ð ½ÇÀû ºÐ¼®, 2019³â-2024³â
  • ¿ëµµº° ÇöÀç ¹× Àå·¡ ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø, 2025³â-2032³â
    • ½Å°æÁúȯ
      • ¾ËÃ÷ÇÏÀ̸Ӻ´
      • Ä¡¸Å
      • ±âŸ
    • ¾Ï Áø´Ü ¹× ¿¹ÈÄ
      • °íÇü Á¾¾ç
      • Ç÷¾×Á¾¾ç
    • ½ÉÀå ±â´É Àå¾Ö
      • ½É±Ù°æ»ö
      • ±âŸ
    • °¨¿°ÁõÀÇ Áø´Ü
    • ±âŸ
  • ÃÖÁ¾ »ç¿ëÀÚº° ½ÃÀå ¸Å·Â ºÐ¼®

Á¦10Àå ÃÖÁ¾ »ç¿ëÀÚº° ¼¼°è ½ÃÀå ºÐ¼®

  • ¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
  • ÃÖÁ¾ »ç¿ëÀÚº° ½ÃÀå ±Ô¸ðÀÇ ¿ª»çÀû ºÐ¼®, 2019³â-2024³â
  • ÃÖÁ¾ »ç¿ëÀÚº° ÇöÀç ¹× Àå·¡ ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø, 2025³â-2032³â
    • º´¿ø
    • Àü¹®Áø´Ü¼¾ÅÍ
    • ¾Ï ¿¬±¸¼¾ÅÍ
    • Çмú¿¬±¸±â°ü
  • ÃÖÁ¾ »ç¿ëÀÚº° ½ÃÀå ¸Å·Â ºÐ¼®

Á¦11Àå Áö¿ªº° ¼¼°è ½ÃÀå ºÐ¼®

  • ¼Ò°³
  • Áö¿ªº° ½ÃÀå ±Ô¸ðÀÇ ¿ª»çÀû ºÐ¼®, 2019³â-2024³â
  • Áö¿ªº° ÇöÀç ¹× Àå·¡ ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø, 2025³â-2032³â
    • ºÏ¹Ì
    • ¶óƾ¾Æ¸Þ¸®Ä«
    • µ¿¾Æ½Ã¾Æ
    • ³²¾Æ½Ã¾Æ ¹× ÅÂÆò¾ç
    • ¼­À¯·´
    • µ¿À¯·´
    • Á߾ӾƽþÆ
    • ·¯½Ã¾Æ¿Í º§·Î·ç½Ã
    • ¹ßÄ­ ¹Ýµµ ¹× ¹ßÆ® ±¹°¡
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • Áö¿ªº° ½ÃÀå ¸Å·Â ºÐ¼®

Á¦12Àå ºÏ¹Ì ½ÃÀå ºÐ¼®

Á¦13Àå ¶óÆ¾¾Æ¸Þ¸®Ä« ½ÃÀå ºÐ¼®

Á¦14Àå µ¿¾Æ½Ã¾Æ ½ÃÀå ºÐ¼®

Á¦15Àå ³²¾Æ½Ã¾Æ¡¤ÅÂÆò¾ç Áö¿ª ½ÃÀå ºÐ¼®

Á¦16Àå ¼­À¯·´ ½ÃÀå ºÐ¼®

Á¦17Àå µ¿À¯·´ ½ÃÀå ºÐ¼®

Á¦18Àå Áß¾Ó¾Æ½Ã¾Æ ½ÃÀå ºÐ¼®

Á¦19Àå ·¯½Ã¾Æ¿Í º§·Î·ç½Ã ½ÃÀå ºÐ¼®

Á¦20Àå ¹ßÄ­ ¹Ýµµ ¹× ¹ßÆ® ±¹°¡ÀÇ ¾Æ½Ã¾Æ ½ÃÀå ºÐ¼®

Á¦21Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«(MEA) ½ÃÀå ºÐ¼®

Á¦22Àå ½ÃÀå ±¸Á¶ ºÐ¼®

  • ±â¾÷ Tierº° ½ÃÀå ºÐ¼®
  • ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
  • ½ÃÀåÇöÀçºÐ¼®

Á¦23Àå °æÀï ºÐ¼®

  • °æÀï ´ë½Ãº¸µå
  • °æÀï º¥Ä¡¸¶Å·
  • °æÀïÀÇ »ó¼¼
    • Eli Lilly and Company
    • Blue Earth Diagnostics
    • Lantheus
    • Siemens Healthcare Private Limited
    • GE Healthcare
    • Advanced Accelerator Applications(Novartis)
    • University of Lowa HealthCare
    • Telix Pharmaceuticals Limited
    • Jubilant Radiopharma
    • TRASIS
    • RadioMedix Inc.
    • IBA Radiopharma Solutions
    • Piramal Imaging(Life Molecular Imaging)
    • Cardinal Health
    • DuchemBio, Co., Ltd

Á¦24Àå ÀüÁ¦¿Í »ç¿ëµÇ´Â ¾à¾î

Á¦25Àå Á¶»ç ¹æ¹ý

SHW 25.08.14

Persistence Market Research has recently released a comprehensive report on the worldwide market for PET radioactive tracers. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.

Key Insights:

  • PET Radioactive Tracers Market Size (2025E): USD 1,069.8 Million
  • Projected Market Value (2032F): USD 1,706.7 Million
  • Global Market Growth Rate (CAGR 2025 to 2032): 6.9%

PET Radioactive Tracers Market - Report Scope:

Positron Emission Tomography (PET) radioactive tracers are critical components in nuclear medicine imaging, enabling real-time visualization of physiological processes at the molecular level. These tracers, primarily labeled with isotopes such as Fluorine-18, Carbon-11, and Gallium-68, are widely used for oncology, cardiology, and neurology applications. The PET radioactive tracers market serves hospitals, diagnostic imaging centers, and research institutions, supporting accurate diagnosis, disease staging, therapy monitoring, and drug development. Market growth is driven by the increasing prevalence of cancer and neurological disorders, rising demand for advanced imaging modalities, and the expanding use of PET imaging in clinical and preclinical settings.

Market Growth Drivers:

The global PET radioactive tracers market is propelled by several factors, including the growing burden of chronic diseases such as cancer and Alzheimer's disease, which require precise and early diagnostic imaging. The rising adoption of hybrid imaging technologies like PET/CT and PET/MRI systems further stimulates tracer demand. Continued innovation in tracer development, including radiopharmaceuticals targeting specific receptors and metabolic pathways, enhances diagnostic accuracy and broadens clinical utility. Moreover, government funding for molecular imaging research, favorable reimbursement scenarios in developed regions, and increasing awareness among clinicians regarding PET's clinical benefits contribute to robust market growth.

Market Restraints:

Despite a promising outlook, the PET radioactive tracers market faces several constraints. These include the high cost of PET imaging procedures and the short half-life of tracers, which necessitates proximity to cyclotron facilities and reliable radiopharmaceutical supply chains. Regulatory hurdles in the approval and production of new tracers, along with complex logistics for handling and transporting radioactive materials, create operational challenges. Additionally, limited access to PET imaging in low-resource settings and a shortage of skilled nuclear medicine professionals hinder widespread adoption, particularly in emerging economies.

Market Opportunities:

The PET radioactive tracers market presents significant growth opportunities fueled by technological advances in radiotracer development and automation in radiopharmacy. The emergence of novel tracers for immuno-oncology, cardiovascular imaging, and neurodegenerative disease monitoring expands clinical applications and supports precision medicine approaches. The increasing establishment of PET imaging facilities in developing countries, coupled with public-private partnerships to improve radiopharmaceutical infrastructure, offers untapped potential. Furthermore, collaborations between pharmaceutical companies and imaging solution providers to develop companion diagnostics for targeted therapies strengthen the market's future prospects.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the PET radioactive tracers market globally?
  • Which isotopes and clinical applications are driving tracer utilization across imaging centers?
  • How are regulatory frameworks and technological innovations shaping the competitive landscape?
  • Who are the key players in the PET radioactive tracers market, and what strategies are they adopting?
  • What are the emerging trends and future directions for tracer development and adoption?

Competitive Intelligence and Business Strategy:

These companies invest in R&D to develop new fluorinated tracers, streamline synthesis procedures, and ensure regulatory compliance. Partnerships with academic institutions, pharmaceutical firms, and cyclotron manufacturers enhance tracer availability and support clinical research. Moreover, emphasis on automation, GMP-compliant production facilities, and distribution network expansion enables key players to maintain competitive advantage and meet the growing global demand.

Key Companies Profiled:

  • Eli Lilly and Company
  • Blue Earth Diagnostics
  • Lantheus
  • Siemens Healthcare Private Limited
  • GE Healthcare
  • Advanced Accelerator Applications (Novartis)
  • University of Lowa HealthCare
  • Telix Pharmaceuticals Limited
  • Jubilant Radiopharma
  • TRASIS
  • RadioMedix Inc.
  • IBA Radiopharma Solutions
  • Piramal Imaging (Life Molecular Imaging)
  • Cardinal Health
  • DuchemBio, Co. Ltd.

PET Radioactive Tracers Market Research Segmentation:

Product:

  • F-18
    • * Florbetapir
    • * Florbetaben
    • * Flutemetamol
    • * Fludeoxyglucose
    • * Sodium Fluoride
    • * Others
  • C-11
    • * Choline
    • * Methionine
    • * Others
  • Ga-68
    • * DOTA-TOC
    • * DOTATATE
    • * DOTANOC
    • * Others
  • O-15
  • N-13
  • Cu-64

Application:

  • Neurological Disorders
    • * Alzheimer's Disease
    • * Dementia
    • * Others
  • Cancer Diagnosis & Prognosis
    • * Solid Tumors
    • * Hematology Tumors
  • Cardiac Dysfunctions
    • * Myocardial Infarction
    • * Others
  • Infectious Disease Diagnosis
  • Others

End User:

  • Hospitals
  • Speciality Diagnostic Centers
  • Cancer Research Centers
  • Academic & Research Institutes

Region:

  • North America
  • Latin America
  • East Asia
  • South Asia & Pacific
  • Western Europe
  • Eastern Europe
  • Central Asia
  • Russia & Belarus
  • Balkan & Baltic Countries
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusion and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Innovation / Development Trends

4. Key Success Factors

  • 4.1. PET Scanner Installed Base Scenario
  • 4.2. Number of PET Scans, By Country
  • 4.3. Disease Epidemiology
  • 4.4. Product Adoption/Usage Analysis
  • 4.5. Regulatory Approval Pathway
  • 4.6. Reimbursement Scenario
  • 4.7. Technology Advancements
  • 4.8. Good Manufacturing Practice (cGMP)
  • 4.9. Value Chain Analysis
  • 4.10. Quality Standards/Accreditations
  • 4.11. PESTEL Analysis
  • 4.12. Porter's Analysis

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Outlook
    • 5.1.2. Global Healthcare Expenditure Outlook
    • 5.1.3. Oncology Spending
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Development of Novel Products
    • 5.2.2. Regulatory Imposition
    • 5.2.3. Increasing Spending on Targeted Therapies
    • 5.2.4. Increasing Prevalence of Cancer
    • 5.2.5. Strategic Mergers and Acquisitions among Local Players
    • 5.2.6. Rising Awareness towards Development of Disease
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. 2021 Market Scenario
  • 6.2. COVID-19 and Impact Analysis
    • 6.2.1. By Product
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Region

7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2019-2024 and Forecast, 2025-2032

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2024
  • 7.2. Current and Future Market Value (US$ Mn) Projections, 2025-2032
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2019-2024 and Forecast 2025-2032, By Product

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Mn) Analysis By Product, 2019-2024
  • 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2025-2032
    • 8.3.1. F-18
      • 8.3.1.1. Florbetapir
      • 8.3.1.2. Florbetaben
      • 8.3.1.3. Flutemetamol
      • 8.3.1.4. Fludeoxyglucose
      • 8.3.1.5. Sodium Fluoride
      • 8.3.1.6. Others
    • 8.3.2. C-11
      • 8.3.2.1. Choline
      • 8.3.2.2. Methionine
      • 8.3.2.3. Others
    • 8.3.3. Ga-68
      • 8.3.3.1. DOTA-TOC
      • 8.3.3.2. DOTATATE
      • 8.3.3.3. DOTANOC
      • 8.3.3.4. Others
    • 8.3.4. O-15
    • 8.3.5. N-13
    • 8.3.6. Cu-64
  • 8.4. Market Attractiveness Analysis By End User

9. Global Market Analysis 2019-2024 and Forecast 2025-2032, By Application

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) Analysis By Application, 2019-2024
  • 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Application, 2025-2032
    • 9.3.1. Neurological Disorders
      • 9.3.1.1. Alzheimer's Disease
      • 9.3.1.2. Dementia
      • 9.3.1.3. Others
    • 9.3.2. Cancer Diagnosis & Prognosis
      • 9.3.2.1. Solid Tumor
      • 9.3.2.2. Hematology Tumor
    • 9.3.3. Cardiac Dysfunctions
      • 9.3.3.1. Myocardial Infarction
      • 9.3.3.2. Others
    • 9.3.4. Infectious disease Diagnosis
    • 9.3.5. Others
  • 9.4. Market Attractiveness Analysis By End User

10. Global Market Analysis 2019-2024 and Forecast 2025-2032, By End User

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Mn) Analysis By End User, 2019-2024
  • 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2025-2032
    • 10.3.1. Hospitals
    • 10.3.2. Speciality Diagnostic Centers
    • 10.3.3. Cancer Research Centers
    • 10.3.4. Academic & Research Institutes
  • 10.4. Market Attractiveness Analysis By End User

11. Global Market Analysis 2019-2024 and Forecast 2025-2032, By Region

  • 11.1. Introduction
  • 11.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2024
  • 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2025-2032
    • 11.3.1. North America
    • 11.3.2. Latin America
    • 11.3.3. East Asia
    • 11.3.4. South Asia & Pacific
    • 11.3.5. Western Europe
    • 11.3.6. Eastern Europe
    • 11.3.7. Central Asia
    • 11.3.8. Russia & Belarus
    • 11.3.9. Balkan & Baltic Countries
    • 11.3.10. Middle East & Africa
  • 11.4. Market Attractiveness Analysis By Region

12. North America Market Analysis 2019-2024 and Forecast 2025-2032

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
  • 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025-2032
    • 12.3.1. By Country
      • 12.3.1.1. U.S.
      • 12.3.1.2. Canada
    • 12.3.2. By Product
    • 12.3.3. By Application
    • 12.3.4. By End User
  • 12.4. Market Attractiveness Analysis
    • 12.4.1. By Country
    • 12.4.2. By Product
    • 12.4.3. By Application
    • 12.4.4. By End User
  • 12.5. Key Market Trends
  • 12.6. Drivers and Restraints - Impact Analysis
  • 12.7. Key Players - Intensity Mapping
  • 12.8. Country Level Analysis & Forecast
    • 12.8.1. U.S. Market
      • 12.8.1.1. Introduction
      • 12.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.1.2.1. By Product
        • 12.8.1.2.2. By Application
        • 12.8.1.2.3. By End User
    • 12.8.2. Canada Market
      • 12.8.2.1. Introduction
      • 12.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.2.2.1. By Product
        • 12.8.2.2.2. By Application
        • 12.8.2.2.3. By End User

13. Latin America Market Analysis 2019-2024 and Forecast 2025-2032

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
  • 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025-2032
    • 13.3.1. By Country
      • 13.3.1.1. Brazil
      • 13.3.1.2. Argentina
      • 13.3.1.3. Mexico
      • 13.3.1.4. Rest of Latin America
    • 13.3.2. By Product
    • 13.3.3. By Application
    • 13.3.4. By End User
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Product
    • 13.4.3. By Application
    • 13.4.4. By End User
  • 13.5. Key Market Trends
  • 13.6. Drivers and Restraints - Impact Analysis
  • 13.7. Key Players - Intensity Mapping
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. Brazil Market
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.1.2.1. By Product
        • 13.8.1.2.2. By Application
        • 13.8.1.2.3. By End User
    • 13.8.2. Argentina Market
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.2.2.1. By Product
        • 13.8.2.2.2. By Application
        • 13.8.2.2.3. By End User
    • 13.8.3. Mexico Market
      • 13.8.3.1. Introduction
      • 13.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.3.2.1. By Product
        • 13.8.3.2.2. By Application
        • 13.8.3.2.3. By End User

14. East Asia Market Analysis 2019-2024 and Forecast 2025-2032

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
  • 14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025-2032
    • 14.3.1. By Country
      • 14.3.1.1. China
      • 14.3.1.2. Japan
      • 14.3.1.3. South Korea
    • 14.3.2. By Product
    • 14.3.3. By Application
    • 14.3.4. By End User
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Product
    • 14.4.3. By Application
    • 14.4.4. By End User
  • 14.5. Key Market Trends
  • 14.6. Drivers and Restraints - Impact Analysis
  • 14.7. Key Players - Intensity Mapping
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. China Market
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.1.2.1. By Product
        • 14.8.1.2.2. By Application
        • 14.8.1.2.3. By End User
    • 14.8.2. Japan Market
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.2.2.1. By Product
        • 14.8.2.2.2. By Application
        • 14.8.2.2.3. By End User
    • 14.8.3. South Korea Market
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.3.2.1. By Product
        • 14.8.3.2.2. By Application
        • 14.8.3.2.3. By End User

15. South Asia & Pacific Market Analysis 2019-2024 and Forecast 2025-2032

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
  • 15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025-2032
    • 15.3.1. By Country
      • 15.3.1.1. India
      • 15.3.1.2. Indonesia
      • 15.3.1.3. Thailand
      • 15.3.1.4. Philippines
      • 15.3.1.5. Malaysia
      • 15.3.1.6. Vietnam
      • 15.3.1.7. Rest of ASEAN
      • 15.3.1.8. Australia & New Zealand
    • 15.3.2. By Product
    • 15.3.3. By Application
    • 15.3.4. By End User
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Product
    • 15.4.3. By Application
    • 15.4.4. By End User
  • 15.5. Key Market Trends
  • 15.6. Drivers and Restraints - Impact Analysis
  • 15.7. Key Players - Intensity Mapping
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. India Market
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.1.2.1. By Product
        • 15.8.1.2.2. By Application
        • 15.8.1.2.3. By End User
    • 15.8.2. Indonesia Market
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.2.2.1. By Product
        • 15.8.2.2.2. By Application
        • 15.8.2.2.3. By End User
    • 15.8.3. Thailand Market
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.3.2.1. By Product
        • 15.8.3.2.2. By Application
        • 15.8.3.2.3. By End User
    • 15.8.4. Philippines Market
      • 15.8.4.1. Introduction
      • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.4.2.1. By Product
        • 15.8.4.2.2. By Application
        • 15.8.4.2.3. By End User
    • 15.8.5. Malaysia Market
      • 15.8.5.1. Introduction
      • 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.5.2.1. By Product
        • 15.8.5.2.2. By Application
        • 15.8.5.2.3. By End User
    • 15.8.6. Vietnam Market
      • 15.8.6.1. Introduction
      • 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.6.2.1. By Product
        • 15.8.6.2.2. By Application
        • 15.8.6.2.3. By End User
    • 15.8.7. Australia & New Zealand Market
      • 15.8.7.1. Introduction
      • 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.7.2.1. By Product
        • 15.8.7.2.2. By Application
        • 15.8.7.2.3. By End User

16. Western Europe Market Analysis 2019-2024 and Forecast 2025-2032

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
  • 16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025-2032
    • 16.3.1. By Country
      • 16.3.1.1. Germany
      • 16.3.1.2. France
      • 16.3.1.3. Spain
      • 16.3.1.4. Italy
      • 16.3.1.5. BENELUX
      • 16.3.1.6. Nordic Countries
      • 16.3.1.7. United Kingdom
    • 16.3.2. By Product
    • 16.3.3. By Application
    • 16.3.4. By End User
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Product
    • 16.4.3. By Application
    • 16.4.4. By End User
  • 16.5. Key Market Trends
  • 16.6. Drivers and Restraints - Impact Analysis
  • 16.7. Key Players - Intensity Mapping
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. Germany Market
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.1.2.1. By Product
        • 16.8.1.2.2. By Application
        • 16.8.1.2.3. By End User
    • 16.8.2. France Market
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.2.2.1. By Product
        • 16.8.2.2.2. By Application
        • 16.8.2.2.3. By End User
    • 16.8.3. Spain Market
      • 16.8.3.1. Introduction
      • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.3.2.1. By Product
        • 16.8.3.2.2. By Application
        • 16.8.3.2.3. By End User
    • 16.8.4. Italy Market
      • 16.8.4.1. Introduction
      • 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.4.2.1. By Product
        • 16.8.4.2.2. By Application
        • 16.8.4.2.3. By End User
    • 16.8.5. BENULUX Market
      • 16.8.5.1. Introduction
      • 16.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.5.2.1. By Product
        • 16.8.5.2.2. By Application
        • 16.8.5.2.3. By End User
    • 16.8.6. Nordic Countries Market
      • 16.8.6.1. Introduction
      • 16.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.6.2.1. By Product
        • 16.8.6.2.2. By Application
        • 16.8.6.2.3. By End User
    • 16.8.7. U.K. Market
      • 16.8.7.1. Introduction
      • 16.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.7.2.1. By Product
        • 16.8.7.2.2. By Application
        • 16.8.7.2.3. By End User

17. Eastern Europe Market Analysis 2019-2024 and Forecast 2025-2032

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
  • 17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025-2032
    • 17.3.1. By Country
      • 17.3.1.1. Poland
      • 17.3.1.2. Hungary
      • 17.3.1.3. Romania
      • 17.3.1.4. Czech Republic
      • 17.3.1.5. Rest of Eastern Europe
    • 17.3.2. By Product
    • 17.3.3. By Application
    • 17.3.4. By End User
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Product
    • 17.4.3. By Application
    • 17.4.4. By End User
  • 17.5. Key Market Trends
  • 17.6. Drivers and Restraints - Impact Analysis
  • 17.7. Key Players - Intensity Mapping
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. Poland Market
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.1.2.1. By Product
        • 17.8.1.2.2. By Application
        • 17.8.1.2.3. By End User
    • 17.8.2. Hungary Market
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.2.2.1. By Product
        • 17.8.2.2.2. By Application
        • 17.8.2.2.3. By End User
    • 17.8.3. Romania Market
      • 17.8.3.1. Introduction
      • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.3.2.1. By Product
        • 17.8.3.2.2. By Application
        • 17.8.3.2.3. By End User
    • 17.8.4. Czech Republic Market
      • 17.8.4.1. Introduction
      • 17.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.4.2.1. By Product
        • 17.8.4.2.2. By Application
        • 17.8.4.2.3. By End User

18. Central Asia Market Analysis 2019-2024 and Forecast 2025-2032

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
  • 18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025-2032
    • 18.3.1. By Product
    • 18.3.2. By Application
    • 18.3.3. By End User
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Product
    • 18.4.2. By Application
    • 18.4.3. By End User
  • 18.5. Key Market Trends
  • 18.6. Drivers and Restraints - Impact Analysis
  • 18.7. Key Players - Intensity Mapping

19. Russia & Belarus Market Analysis 2019-2024 and Forecast 2025-2032

  • 19.1. Introduction
  • 19.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
  • 19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025-2032
    • 19.3.1. By Product
    • 19.3.2. By Application
    • 19.3.3. By End User
  • 19.4. Market Attractiveness Analysis
    • 19.4.1. By Product
    • 19.4.2. By Application
    • 19.4.3. By End User
  • 19.5. Key Market Trends
  • 19.6. Drivers and Restraints - Impact Analysis
  • 19.7. Key Players - Intensity Mapping

20. Balkan & Baltic Countries Asia Market Analysis 2019-2024 and Forecast 2025-2032

  • 20.1. Introduction
  • 20.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
  • 20.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025-2032
    • 20.3.1. By Product
    • 20.3.2. By Application
    • 20.3.3. By End User
  • 20.4. Market Attractiveness Analysis
    • 20.4.1. By Product
    • 20.4.2. By Application
    • 20.4.3. By End User
  • 20.5. Key Market Trends
  • 20.6. Drivers and Restraints - Impact Analysis
  • 20.7. Key Players - Intensity Mapping

21. Middle East and Africa (MEA) Market Analysis 2019-2024 and Forecast 2025-2032

  • 21.1. Introduction
  • 21.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
  • 21.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025-2032
    • 21.3.1. By Country
      • 21.3.1.1. GCC Countries
      • 21.3.1.2. Kingdom of Saudi Arabia
      • 21.3.1.3. Turkiye
      • 21.3.1.4. Northern Africa
      • 21.3.1.5. South Africa
      • 21.3.1.6. Israel
    • 21.3.2. By Product
    • 21.3.3. By Application
    • 21.3.4. By End User
  • 21.4. Market Attractiveness Analysis
    • 21.4.1. By Country
    • 21.4.2. By Product
    • 21.4.3. By Application
    • 21.4.4. By End User
  • 21.5. Key Market Trends
  • 21.6. Drivers and Restraints - Impact Analysis
  • 21.7. Key Players - Intensity Mapping
  • 21.8. Country Level Analysis & Forecast
    • 21.8.1. GCC Countries Market
      • 21.8.1.1. Introduction
      • 21.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 21.8.1.2.1. By Product
        • 21.8.1.2.2. By Application
        • 21.8.1.2.3. By End User
    • 21.8.2. Kingdom of Saudi Arabia Market
      • 21.8.2.1. Introduction
      • 21.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 21.8.2.2.1. By Product
        • 21.8.2.2.2. By Application
        • 21.8.2.2.3. By End User
    • 21.8.3. Turkiye Market
      • 21.8.3.1. Introduction
      • 21.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 21.8.3.2.1. By Product
        • 21.8.3.2.2. By Application
        • 21.8.3.2.3. By End User
    • 21.8.4. Northern Africa Market
      • 21.8.4.1. Introduction
      • 21.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 21.8.4.2.1. By Product
        • 21.8.4.2.2. By Application
        • 21.8.4.2.3. By End User
    • 21.8.5. South Africa Market
      • 21.8.5.1. Introduction
      • 21.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 21.8.5.2.1. By Product
        • 21.8.5.2.2. By Application
        • 21.8.5.2.3. By End User
    • 21.8.6. Israel Market
      • 21.8.6.1. Introduction
      • 21.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 21.8.6.2.1. By Product
        • 21.8.6.2.2. By Application
        • 21.8.6.2.3. By End User

22. Market Structure Analysis

  • 22.1. Market Analysis by Tier of Companies
  • 22.2. Market Share Analysis of Top Players
  • 22.3. Market Presence Analysis
    • 22.3.1. Regional footprint of Players
    • 22.3.2. Platform Type foot print by Players
    • 22.3.3. Channel Foot Print by Players

23. Competition Analysis

  • 23.1. Competition Dashboard
  • 23.2. Competition Benchmarking
  • 23.3. Competition Deep Dive
    • 23.3.1. Eli Lilly and Company
      • 23.3.1.1. Company Overview
      • 23.3.1.2. Product Portfolio
      • 23.3.1.3. Sales Footprint
      • 23.3.1.4. Key Financials
      • 23.3.1.5. SWOT Analysis
      • 23.3.1.6. Key Developments
      • 23.3.1.7. Strategy Overview
        • 23.3.1.7.1. Channel Strategy
        • 23.3.1.7.2. Marketing Strategy
        • 23.3.1.7.3. Product Strategy
    • 23.3.2. Blue Earth Diagnostics
      • 23.3.2.1. Company Overview
      • 23.3.2.2. Product Portfolio
      • 23.3.2.3. Sales Footprint
      • 23.3.2.4. Key Financials
      • 23.3.2.5. SWOT Analysis
      • 23.3.2.6. Key Developments
      • 23.3.2.7. Strategy Overview
        • 23.3.2.7.1. Channel Strategy
        • 23.3.2.7.2. Marketing Strategy
        • 23.3.2.7.3. Product Strategy
    • 23.3.3. Lantheus
      • 23.3.3.1. Company Overview
      • 23.3.3.2. Product Portfolio
      • 23.3.3.3. Sales Footprint
      • 23.3.3.4. Key Financials
      • 23.3.3.5. SWOT Analysis
      • 23.3.3.6. Key Developments
      • 23.3.3.7. Strategy Overview
        • 23.3.3.7.1. Channel Strategy
        • 23.3.3.7.2. Marketing Strategy
        • 23.3.3.7.3. Product Strategy
    • 23.3.4. Siemens Healthcare Private Limited
      • 23.3.4.1. Company Overview
      • 23.3.4.2. Product Portfolio
      • 23.3.4.3. Sales Footprint
      • 23.3.4.4. Key Financials
      • 23.3.4.5. SWOT Analysis
      • 23.3.4.6. Key Developments
      • 23.3.4.7. Strategy Overview
        • 23.3.4.7.1. Channel Strategy
        • 23.3.4.7.2. Marketing Strategy
        • 23.3.4.7.3. Product Strategy
    • 23.3.5. GE Healthcare
      • 23.3.5.1. Company Overview
      • 23.3.5.2. Product Portfolio
      • 23.3.5.3. Sales Footprint
      • 23.3.5.4. Key Financials
      • 23.3.5.5. SWOT Analysis
      • 23.3.5.6. Key Developments
      • 23.3.5.7. Strategy Overview
        • 23.3.5.7.1. Channel Strategy
        • 23.3.5.7.2. Marketing Strategy
        • 23.3.5.7.3. Product Strategy
    • 23.3.6. Advanced Accelerator Applications (Novartis)
      • 23.3.6.1. Company Overview
      • 23.3.6.2. Product Portfolio
      • 23.3.6.3. Sales Footprint
      • 23.3.6.4. Key Financials
      • 23.3.6.5. SWOT Analysis
      • 23.3.6.6. Key Developments
      • 23.3.6.7. Strategy Overview
        • 23.3.6.7.1. Channel Strategy
        • 23.3.6.7.2. Marketing Strategy
        • 23.3.6.7.3. Product Strategy
    • 23.3.7. University of Lowa HealthCare
      • 23.3.7.1. Company Overview
      • 23.3.7.2. Product Portfolio
      • 23.3.7.3. Sales Footprint
      • 23.3.7.4. Key Financials
      • 23.3.7.5. SWOT Analysis
      • 23.3.7.6. Key Developments
      • 23.3.7.7. Strategy Overview
        • 23.3.7.7.1. Channel Strategy
        • 23.3.7.7.2. Marketing Strategy
        • 23.3.7.7.3. Product Strategy
    • 23.3.8. Telix Pharmaceuticals Limited
      • 23.3.8.1. Company Overview
      • 23.3.8.2. Product Portfolio
      • 23.3.8.3. Sales Footprint
      • 23.3.8.4. Key Financials
      • 23.3.8.5. SWOT Analysis
      • 23.3.8.6. Key Developments
      • 23.3.8.7. Strategy Overview
        • 23.3.8.7.1. Channel Strategy
        • 23.3.8.7.2. Marketing Strategy
        • 23.3.8.7.3. Product Strategy
    • 23.3.9. Jubilant Radiopharma
      • 23.3.9.1. Company Overview
      • 23.3.9.2. Product Portfolio
      • 23.3.9.3. Sales Footprint
      • 23.3.9.4. Key Financials
      • 23.3.9.5. SWOT Analysis
      • 23.3.9.6. Key Developments
      • 23.3.9.7. Strategy Overview
        • 23.3.9.7.1. Channel Strategy
        • 23.3.9.7.2. Marketing Strategy
        • 23.3.9.7.3. Product Strategy
    • 23.3.10. TRASIS
      • 23.3.10.1. Company Overview
      • 23.3.10.2. Product Portfolio
      • 23.3.10.3. Sales Footprint
      • 23.3.10.4. Key Financials
      • 23.3.10.5. SWOT Analysis
      • 23.3.10.6. Key Developments
      • 23.3.10.7. Strategy Overview
        • 23.3.10.7.1. Channel Strategy
        • 23.3.10.7.2. Marketing Strategy
        • 23.3.10.7.3. Product Strategy
    • 23.3.11. RadioMedix Inc.
      • 23.3.11.1. Company Overview
      • 23.3.11.2. Product Portfolio
      • 23.3.11.3. Sales Footprint
      • 23.3.11.4. Key Financials
      • 23.3.11.5. SWOT Analysis
      • 23.3.11.6. Key Developments
      • 23.3.11.7. Strategy Overview
        • 23.3.11.7.1. Channel Strategy
        • 23.3.11.7.2. Marketing Strategy
        • 23.3.11.7.3. Product Strategy
    • 23.3.12. IBA Radiopharma Solutions
      • 23.3.12.1. Company Overview
      • 23.3.12.2. Product Portfolio
      • 23.3.12.3. Sales Footprint
      • 23.3.12.4. Key Financials
      • 23.3.12.5. SWOT Analysis
      • 23.3.12.6. Key Developments
      • 23.3.12.7. Strategy Overview
        • 23.3.12.7.1. Channel Strategy
        • 23.3.12.7.2. Marketing Strategy
        • 23.3.12.7.3. Product Strategy
    • 23.3.13. Piramal Imaging (Life Molecular Imaging)
      • 23.3.13.1. Company Overview
      • 23.3.13.2. Product Portfolio
      • 23.3.13.3. Sales Footprint
      • 23.3.13.4. Key Financials
      • 23.3.13.5. SWOT Analysis
      • 23.3.13.6. Key Developments
      • 23.3.13.7. Strategy Overview
        • 23.3.13.7.1. Channel Strategy
        • 23.3.13.7.2. Marketing Strategy
        • 23.3.13.7.3. Product Strategy
    • 23.3.14. Cardinal Health
      • 23.3.14.1. Company Overview
      • 23.3.14.2. Product Portfolio
      • 23.3.14.3. Sales Footprint
      • 23.3.14.4. Key Financials
      • 23.3.14.5. SWOT Analysis
      • 23.3.14.6. Key Developments
      • 23.3.14.7. Strategy Overview
        • 23.3.14.7.1. Channel Strategy
        • 23.3.14.7.2. Marketing Strategy
        • 23.3.14.7.3. Product Strategy
    • 23.3.15. DuchemBio, Co., Ltd
      • 23.3.15.1. Company Overview
      • 23.3.15.2. Product Portfolio
      • 23.3.15.3. Sales Footprint
      • 23.3.15.4. Key Financials
      • 23.3.15.5. SWOT Analysis
      • 23.3.15.6. Key Developments
      • 23.3.15.7. Strategy Overview
        • 23.3.15.7.1. Channel Strategy
        • 23.3.15.7.2. Marketing Strategy
        • 23.3.15.7.3. Product Strategy

24. Assumptions and Acronyms Used

25. Research Methodology

»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦